Loading...
Loading...
Contributors:
Dataset URI:
10.3389/fpubh.2026.1940487.s002ObjectiveThe HER2 immunohistochemical (IHC) score of breast cancer is a critical precursor for determining eligibility for anti-HER2 targeted therapy, as the final HER2 status (positive/negative/low) is determined by IHC results combined with FISH confirmation for equivocal 2 + cases according to ASCO/CAP guidelines. However, most existing artificial intelligence methods separate the detection of invasive cancer regions from HER2 grading and fail to adequately model the spatial heterogeneity of whole-slide tumors. This study proposes an end-to-end intelligent HER2 grading framework that integrates automated detection of invasive cancer regions with hierarchical graph reasoning, enabling automated and precise evaluation of HER2 IHC in breast cancer.MethodA coarse-to-fine automated HER2 grading framework was developed. First, invasive tumor regions were automatically identified through supervised multi-scale tissue segmentation. Within the detected regions, patch-level HER2 grading integrates Delaunay cell image features with self-supervised visual representations, while WSI-level spatial representations model tumor heterogeneity to achieve fully automated HER2 grading across whole-slide images. The framework was trained using data from two scanning platforms and externally validated on 82 independent WSI samples from a third platform.ResultsIn independent external validation, the Dice coefficient for invasive region detection reached 0.89 (on 50 WSI images); the accuracy rate of HER2 grading at the patch level was 96.49% (95% CI, 96.08–96.87%) (7,924 patches), while that at the WSI level reached 98.0% (95% CI, 91.5–99.9%) (82 WSI images). The quadratic-weighted Cohen’s κ was 0.97 (95% CI, 0.94–1.00), and all misclassifications at the WSI level were confined to the distinction between HER2 1 + and 2 +.ConclusionThis framework enables fully automated HER2 IHC scoring and interpretation under multicenter and cross-scanner conditions, providing a computational tool for standardized IHC assessment, while final HER2 status determination for 2 + cases still requires FISH validation.
Keyword(s):
artificial intelligence; automated HER2 grading; breast cancer; graph neural network; HER2 immunohistochemistry.
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)